Scarica l'app Stockscreener
9.24
1.81%
-0.17
Dopo l'orario di chiusura:
9.32
0.08
+0.87%
Precedente Chiudi:
$9.41
Aprire:
$9.52
Volume 24 ore:
257.97K
Relative Volume:
0.56
Capitalizzazione di mercato:
$1.24B
Reddito:
$53.99M
Utile/perdita netta:
$-222.30M
Rapporto P/E:
-5.0864
EPS:
-1.8166
Flusso di cassa netto:
$-213.50M
1 W Prestazione:
-6.29%
1M Prestazione:
-6.10%
6M Prestazione:
+58.76%
1 anno Prestazione:
+104.42%
Intervallo 1D:
$9.13
$9.83
Intervallo di 1 settimana:
$9.13
$10.62
Portata 52W:
$3.30
$12.41
Immatics N V Stock (IMTX) Company Profile
Compare IMTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
9.24 | 1.24B | 53.99M | -222.30M | -213.50M | -1.8166 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Iniziato | Guggenheim | Buy |
| 2025-05-28 | Iniziato | Deutsche Bank | Buy |
| 2024-10-07 | Iniziato | Piper Sandler | Overweight |
| 2023-11-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-03-24 | Iniziato | Bryan Garnier | Buy |
| 2020-11-20 | Iniziato | BofA Securities | Buy |
| 2020-09-22 | Iniziato | Goldman | Buy |
| 2020-07-27 | Iniziato | SVB Leerink | Outperform |
| 2020-07-24 | Iniziato | Jefferies | Buy |
Mostra tutto
Immatics N V Borsa (IMTX) Ultime notizie
(IMTX) Risk Channels and Responsive Allocation - Stock Traders Daily
Immatics NV (IMTX) seeing strong enrollment in a key phase 3 trial of drug candidate - MSN
Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate - Yahoo Finance
Can Immatics NV Equity Warrant generate free cash flow2026 Market Sentiment & Target Return Focused Stock Picks - baoquankhu1.vn
Immatics (NASDAQ:IMTX) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Immatics (NASDAQ:IMTX) Shares Gap DownTime to Sell? - MarketBeat
Is Immatics’ 2025 Loss and PRAME Pipeline Push Altering The Investment Case For Immatics (IMTX)? - simplywall.st
Jefferies Financial Group Inc. Takes $10.18 Million Position in Immatics N.V. $IMTX - MarketBeat
Insider Buy: What is the target price for Immatics NV stockDay Trade & Real-Time Volume Triggers - baoquankhu1.vn
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot (NASDAQ:IMTX) - Seeking Alpha
Immatics NV earnings beat by €0.13, revenue topped estimates - Investing.com Nigeria
Wall Street Zen Upgrades Immatics (NASDAQ:IMTX) to "Hold" - MarketBeat
Wall Street Zen Upgrades Immatics (NASDAQ:IMTX) to “Hold” - Defense World
Is Immatics N.V. Equity Warrant stock near bottom after declineGold Moves & Low Risk Growth Stock Ideas - Naître et grandir
Tech Rally: Should I invest in Immatics NV Equity Warrant before earnings2025 Momentum Check & Short-Term Swing Trade Alerts - baoquankhu1.vn
Immatics 2025 Financial Results: Q4 Revenue $23M, Annual Loss $222.2MNews and Statistics - IndexBox
Immatics (NASDAQ:IMTX) Announces Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Immatics Announces Full Year 2025 Financial Results and Business Update - Investing News Network
Immatics: Fourth Quarter Financial Overview - Bitget
Immatics: Q4 Earnings Snapshot - KVUE
IMTX Financial Assets Decline Due to R&D Spending and Exchange L - GuruFocus
Immatics Confirms 2027 Anzu-cel Launch Timeline as PRAME Franchise and Cash Runway Advance - TipRanks
Immatics Earnings Report: Q4 Overview - Benzinga
Immatics (NASDAQ: IMTX) 2025 results show revenue drop and larger net loss - Stock Titan
Immatics N.V Gross Profit | IMTX - MLQ.ai
immatics biotechnologies GmbH (IMTXW) Competitors - Meyka
(IMTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Immatics (NASDAQ:IMTX) Lowered to “Sell” Rating by Wall Street Zen - Defense World
IMTX SEC FilingsImmatics N.V 10-K, 10-Q, 8-K Forms - Stock Titan
Immatics (NASDAQ:IMTX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Immatics N.V. (NASDAQ:IMTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Trade Report: Is PACK a defensive stockWeekly Trading Summary & Advanced Technical Signal Analysis - baoquankhu1.vn
Energy Moves: Is Immatics NV in a long term uptrendPortfolio Risk Summary & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Immatics (NASDAQ:IMTX) Trading Down 5% – Here’s What Happened - Defense World
IMTX PE Ratio & Valuation, Is IMTX Overvalued - Intellectia AI
Is Immatics N.V. a defensive stockQuarterly Trade Report & High Accuracy Swing Entry Alerts - mfd.ru
Aug Gainers: Whats next for Immatics NV Equity Warrant stockTrade Analysis Report & AI Driven Stock Price Forecasts - baoquankhu1.vn
Wall Street Zen Upgrades Immatics (NASDAQ:IMTX) to Hold - MarketBeat
Immatics N.V. (IMTX): Investor Outlook Reveals an 85% Upside Potential Amidst Groundbreaking Cancer Therapies - DirectorsTalk Interviews
RTW INVESTMENTS, LP Increases Stake in Immatics NV - GuruFocus
Can Immatics N.V. Equity Warrant expand into new marketsEarnings Recap Report & Smart Swing Trading Techniques - mfd.ru
Can Immatics N.V. Equity Warrant reach resistance levels soonJuly 2025 Chart Watch & Risk Controlled Stock Pick Alerts - mfd.ru
Will Immatics N.V. (4A3) stock gain from green policiesBuy Signal & Reliable Momentum Entry Alerts - mfd.ru
Immatics (NASDAQ:IMTX) Shares Down 5%Time to Sell? - MarketBeat
Liquidity Mapping Around (IMTX) Price Events - Stock Traders Daily
Exit Recap: Is Immatics NV a cyclical or defensive stockPortfolio Gains Report & Real-Time Market Trend Scan - baoquankhu1.vn
RTW Investments reveals 8.5% Immatics N.V. (IMTX) stake in Schedule 13G/A - Stock Titan
Institution Moves: Is Flushing Financial Corporation attractive at current valuationQuarterly Performance Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
What Immatics (IMTX)'s Melanoma Orphan Drug Designation Means For Shareholders - Sahm
Immatics N.V. (IMTX) Stock Analysis: Near 93% Upside Potential Drives Investor Interest - DirectorsTalk Interviews
Does Immatics N.V. stock have upside surprise potentialQuarterly Earnings Report & Daily Technical Forecast Reports - mfd.ru
Immatics N V Azioni (IMTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):